Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6672550 | 0.92 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6685209 | 0.85 | PHGDH (0.38) | KMT2AMEN1LMNA | |
| SCHEMBL6677722 | 0.84 | PHGDH (0.42) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6673164 | 0.84 | PHGDH (0.31) | MAPTALDH1A1 | |
| SCHEMBL6672542 | 0.82 | HSD17B10 (0.40) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6674126 | 0.82 | CYP3A4 (0.41) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6674714 | 0.82 | MAPT (0.37) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6674355 | 0.81 | MAPT (0.33) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6672556 | 0.80 | KMT2A (0.38) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6673716 | 0.80 | MAPT (0.33) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1424072-A1 | N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-06-02 | — | — | EP | disclosed |
| US-6683184-B2 | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | MAPT 4877/4885ALDH1A1 58/4885SMN1; SMN2 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.